Your browser doesn't support javascript.
loading
Prevalencia de anticuerpos anti-VHC y del antígeno de superficie de la hepatitis B en pacientes tratados con hemodiálisis / Prevalence of anti-HCV antibodies and of the hepatitis B surface antigen in patients treated with hemodialysis
Martínez Córdova, Zuzet; Peña Fresneda, Natacha.
Affiliation
  • Martínez Córdova, Zuzet; Hospital Clinicoquirúrgico Hermanos Ameijeiras. La Habana. CU
  • Peña Fresneda, Natacha; Instituto de Nefrología Abelardo Buch. La Habana. CU
Rev. cuba. med ; 47(1)ene.-mar. 2008. ilus
Article in Spanish | LILACS | ID: lil-499488
Responsible library: CU1.1
RESUMEN
Se estudiaron 108 pacientes con tratamiento de hemodiálisis para determinar la prevalencia de anticuerpos contra el virus de la hepatitis C (anti-VHC) y del antígeno de superficie de la hepatitis B (HBsAg) empleando la tecnología SUMA. Se obtuvo elevada prevalencia de anticuerpos contra el virus de la hepatitis C (90 por ciento) y menor prevalencia del HBsAg (4 por ciento). Se hallaron títulos protectores de anticuerpos anti-HBsAg en el 91 por ciento de los pacientes. Se observó que los pacientes con niveles de anticuerpos de 10 UI/L resultaron protegidos lo que se corresponde con una respuesta efectiva a nuestro esquema de vacunación y con mejores resultados que lo normalmente reportado para este tipo de paciente (100 UI/L). Se presentaron valores persistentemente normales de actividad enzimática de la enzima glutámico-pirúvica (TGP) en el 65 por ciento de los pacientes, lo que podría indicar una enfermedad crónica y corrobora la frecuente disminución que se observa en la actividad enzimática de la TGP.
ABSTRACT
108 hemodialysis patients were studied to determine the prevalence of antibodies against hepatitis C virus (anti-HCV) and of the hepatitis B surface antigen (HBsAg) by using the SUMA technology. It was obtained an elevated prevalence of antibodies against the hepatitis C virus (90 percent) and a lower prevalence of of HBsAg (4 percent). Titres protecting anti-HBsAg antibodies were found in 91 percent of the patients. It was observed that the patients with antibody levels of 10 UI/L were protected, which corresponds to an effective response to our vaccination scheme and to better results than the ones normally reported for this type of patient (100 UI/L). Persistently normal values of the enzymatic activity of the glutamic piruvic enzyme (GPT) were present in 65 percent of the patients, which could indicate a chronic disease and corroborate the frequent decrease observed in the enzymatic activity of GPT.
Subject(s)
Full text: Available Collection: International databases Health context: SDG3 - Health and Well-Being Health problem: Target 3.3: End transmission of communicable diseases Database: LILACS Main subject: Renal Dialysis / Hepatitis C Antibodies / Hepatitis B Antibodies Type of study: Prevalence study / Risk factors / Screening study Limits: Humans Language: Spanish Journal: Rev. cuba. med Journal subject: Medicine Year: 2008 Document type: Article Affiliation country: Cuba Institution/Affiliation country: Hospital Clinicoquirúrgico Hermanos Ameijeiras/CU / Instituto de Nefrología Abelardo Buch/CU
Full text: Available Collection: International databases Health context: SDG3 - Health and Well-Being Health problem: Target 3.3: End transmission of communicable diseases Database: LILACS Main subject: Renal Dialysis / Hepatitis C Antibodies / Hepatitis B Antibodies Type of study: Prevalence study / Risk factors / Screening study Limits: Humans Language: Spanish Journal: Rev. cuba. med Journal subject: Medicine Year: 2008 Document type: Article Affiliation country: Cuba Institution/Affiliation country: Hospital Clinicoquirúrgico Hermanos Ameijeiras/CU / Instituto de Nefrología Abelardo Buch/CU
...